Duration of correction for human immunodeficiency virus-associated lipoatrophy after retreatment with injectable poly-L-lactic acid.
The Blue Pacific study assessed the effect of injectable poly-L-lactic acid (PLLA) (Sculptra; Dermik Laboratories, a business of Sanofi-Aventis U.S. LLC, Bridgewater, NJ, USA) for the treatment of human immunodeficiency virus (HIV)-associated facial lipoatrophy. This case report describes a patient treated originally with injectable PLLA in the Blue Pacific study, then retreated with injectable PLLA 12 months after completion of his initial treatment sessions. Retreatment was well tolerated and resulted in a correction of facial lipoatrophy for a duration of 2 years 7 months.